A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer

International Journal of Biological Markers

Volumn 27, Issue 3, 2012, Pages

  Trapé, Jaume ^a   Montesinos, Jesus ^a   Catot, Sílvia ^a   Buxó, Josep ^a   Franquesa, Josefina ^a   Sala, Maria ^a   Domenech, Montserrat ^a   Sant, Francesc ^a   Badal, Josep M ^a   Arnau, Anna ^a  

^a Althaia   (Spain)

Author keywords

CA125; CEA; Classification; CYFRA 21 1; Lung neoplasms; Risk factors; Survival; Tumor markers

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867557922     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9314     Document Type: Article

References (19)

1. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 13 Suppl 1: 5-13.
2. Bordoni R. Consensus conference: multimodality management of early-and intermediate-stage non-small cell lung cancer. Oncologist 2008; 13: 945-53.
3. Molina R, Augé JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009; 30: 121-9.
4. Trapé J, Pérez de Olaguer J, Buxó J, López L. Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer. Clin Chem 2005; 51: 219-22.
5. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001; 31: 221-31.
6. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003; 24: 209-18.
7. Trapé J, Buxo J, Pérez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23: 4277-81.
8. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 3: 385-91.
9. Diez M, Torres A, Pollán M, et al. Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer 1994; 73: 1368-76.
10. Ando S, Kimura H, Iwai N, Yamamoto N, Iida T. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. Anticancer Res 2003; 23: 2869-74.
11. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90: 2097-105.
12. Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A. Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol 2008; 134: 1143-9.
13. Ray P, Quantin X, Grenìer J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 1998; 22: 293-304.
14. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3: 457-66.
15. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2008; 7: 613-5.
16. Koch A, Fohlin H, Sörenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009; 4: 326-32.
17. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23: 175-83.
18. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5: 649-52.
19. Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers. Anticancer Res 1999; 19: 2817-9.